Demographics Membranous nephropathy (MN) is one of the most common causes of nephrotic syndrome in Caucasian adults above 40 years. However, it can occur in different ages and ethnicities. The incidence was estimated about 8-10 cases per one…
Membranous nephropathy (MN) is the most common cause of nephrotic syndrome in the Caucasian adult population with an estimated incidence of 8–10 cases per 1 million and commonly seen in males above the age of 40. It is…
Membranous nephropathy is among the most common causes of the nephrotic syndrome in non-diabetic adult. It is an immune complex mediated disease which occurs when circulating antibodies permeate the glomerular basement membrane and form immune complexes with epitopes…
Rituximab, the monoclonal chimeric anti-CD20 antibody, is an effective B-Cell depleting agent and continues to gather data for its use in a wide range of conditions relevant for the Nephrologist. It was also a pre-season favourite in the…
U Penn established an annual one-day seminar in nephrology symposium. This year was titled “New Horizons in Nephrology: Updates in Glomerular Disease”. Dr. Beck from Boston University gave the update on membranous nephropathy (MN). Previously, we discussed his…
A man in his early 60s was being treated for metastatic adenocarcinoma of the lung for 2 years. Recently, he had been complaining of increasing hemoptysis and a PET CT was performed which showed progression of his disease….
A 53-year-old Caucasian male presented with pulmonary embolism, and was found to have nephrotic syndrome. A kidney biopsy showed membranous nephropathy (MN). The disease progressed despite treatment and six years later, the patient underwent a pre-emptive living unrelated…
This is the story of a 64 year old male mason with past medical history notable for hypertension and hyperlipidemia who was referred to me for evaluation of proteinuria. The patient noted onset of lower extremity edema nine…
Take-home points from Mayo Clinic’s Fernando Fervenza’s excellent Renal Grand Rounds this morning, in which he addresses the potential use of rituximab as a treatment for membranous nephropathy: -the “rule of thirds” that we learn about membranous nephropathy (e.g.,…
